Sends email in progress
 
Top news
Scientific news
In CML, the OPTIM-Imatinib study shows that dose adjustment of imatinib by drug monitoring improves the molecular response rate
Leukemia
Report
Published online: 5 December 2015
In CML, the OPTIM-Imatinib study shows that dose adjustment of imatinib by drug...
Dr Philippe Quittet (Hôpital Lapeyronie - CHU de Montpellier)
This study by the French CML group shows the importance of personalised treatment in CML patients in chronic phase (CML-CP) treated with first-line  imatinib (IM). This standard treatment is administered as a single dose 400 mg/d. An analysis of the IRIS study showed that the minimum serum rate (C) min> 1000 ng/mL was...
Read more
CD93 - a new leukaemia stem cell marker in chronic myeloid leukemia
Leukemia
Report
Published online: 5 December 2015
CD93 - a new leukaemia stem cell marker in chronic myeloid leukemia
Pr Claude Preudhomme (CHRU de Lille)
Although tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukaemia (CML), only a small number of patients will completely inhibit their BCR-ABL transcript, probably due to the persistence of leukaemia stem cells (LSC).
Thanks to a microarrays approach comparing CML LSCs to SCs of...
Read more
Can we eradicate CML leukaemia stem cells in « poor responder » patients?
Leukemia
Report
Published online: 5 December 2015
Can we eradicate CML leukaemia stem cells in « poor responder » patients?
Dr Philippe Quittet (Hôpital Lapeyronie - CHU de Montpellier)
Tyrosine kinase inhibitors (TKI) have transformed the prognosis of CML, although today it seems unlikely that they can cure patients. Indeed, quiescent leukaemia stem cells (LSCs) are refractory to TKIs. Furthermore, a small number of patients who do not respond favourably to TKIs may acquire additional cytogenetic
Read more
All scientific articles